Elise Lepicard

Pioneering Research

Over the last ten years, Oracle Cancer Trust has granted over £5m in funding pioneering early-stage research projects. These have paved the way for larger clinical trials to take place to test new drugs, new treatments and new techniques to combat head and neck cancer.

Crucially, without the Oracle ‘seed’ research, these large trials would simply not have been possible; Oracle is filling a research gap. Currently, mainstream funding for head and neck cancer is less than 2% in UK, and in recent years has actually declined. This is even more alarming given it is now the sixth most common form of cancer with cases rising rapidly.

You can read Oracle's Research Strategy here.

Each Oracle research project is rigorously assessed by peer review and independently approved by the Oracle Research Committee. All committees at Oracle are voluntary and non-conflicted.

Oracle is currently supporting five broad areas of research:

Oracle Cancer Trust is a member of the Association of Medical Research Charities (AMRC). We support the principle of using animals in research when it is necessary to advance understanding of health and disease and to develop new treatments. This research only takes place where there is no alternative available. All AMRC member charities support this principle, as outlined in this statement.

In line with this we support the principle of the 3Rs to refine, reduce and replace the use of animals in research and take them into consideration during the application and review process.

Currently mainstream funding for head and neck cancer is less than 2% in UK

Oracle's Three-Year Research Strategy 2017-2020

Download here

In this section


Follow us

Get in touch

Call 020 3875 8991

Email info@oraclecancertrust.org


Oracle Cancer Trust is a registered charity in England and Wales (1142037). A company limited by guarantee. Registered company in England and Wales (7125497). Registered address: 10 Parsons Green House, 27 Parsons Green Lane, London SW6 4HH.